Sugi Predict

Sugi Predict / Compounds / SCHEMBL10161903

SCHEMBL10161903

SCHEMBL10161903

CC(=O)c1ccc2c(c1C)CC[C@@H]2NC(=O)c1cc(C(=O)NCc2ccc(C(F)(F)F)cc2)nc2c(F)cnn12

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADAMTS4 O75173 2/20 0.76
▸ MMP3 P08254 2/20 0.76
▸ MMP13 P45452 2/20 0.76
▸ MMP8 P22894 1/20 0.49
▸ MMP12 P39900 1/20 0.49
▸ KLKB1 P03952 2/20 0.37
▸ TRPV1 Q8NER1 1/20 0.36
▸ DHODH Q02127 3/20 0.36
▸ CYP11B1 P15538 3/20 0.35
▸ CYP11B2 P19099 3/20 0.35
▸ RORC P51449 2/20 0.35
▸ FLT3 P36888 1/20 0.35
▸ TYRO3 Q06418 1/20 0.35
▸ MERTK Q12866 1/20 0.35
▸ GAS6 Q14393 1/20 0.35
▸ PDE2A O00408 2/20 0.34
▸ CHRNA7 P36544 1/20 0.34
▸ PSMD14 O00487 1/20 0.34
▸ STAMBP O95630 1/20 0.34
▸ ADORA3 P0DMS8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10161949 0.93 MMP13 (0.74) ADAMTS4MMP3MMP13MMP8MMP12
SCHEMBL10161919 0.93 MMP13 (0.73) ADAMTS4MMP3MMP13MMP8MMP12
SCHEMBL10162024 0.92 ADAMTS4 (0.70) ADAMTS4MMP3MMP13MMP8MMP12
SCHEMBL10161880 0.92 MMP13 (0.90) ADAMTS4MMP3MMP13MMP8MMP12
SCHEMBL10161904 0.91 MMP13 (0.77) ADAMTS4MMP3MMP13MMP8MMP12
SCHEMBL10161973 0.90 MMP13 (0.76) ADAMTS4MMP3MMP13MMP8MMP12
SCHEMBL10161590 0.90 MMP13 (0.73) ADAMTS4MMP3MMP13MMP8MMP12
SCHEMBL10161918 0.89 MMP13 (0.74) ADAMTS4MMP3MMP13MMP8MMP12
SCHEMBL10161931 0.89 MMP13 (0.74) ADAMTS4MMP3MMP13MMP8MMP12
SCHEMBL10161951 0.89 MMP13 (0.71) ADAMTS4MMP3MMP13MMP8MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 — — US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 — — US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 — — US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 — — US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 — — US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 ADAMTS4 38/4885MMP3 3/4885MMP13 1/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 ADAMTS4 38/4885MMP3 3/4885MMP13 1/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 ADAMTS4 38/4885MMP3 3/4885MMP13 1/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 ADAMTS4 38/4885MMP3 3/4885MMP13 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.